Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data ...

This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of $7.9 billion ...

Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...

The Department of Health says it is "aware" of the jab and is "exploring" how it can be made available "as soon as possible".

Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...

The gap between US drug prices and those abroad is not a market outcome — it is the result of deliberate political and ...

Mounjaro surpassed Keytruda as the world’s top-selling medicine, driven by soaring global demand for obesity and diabetes treatments.

Read all the latest news headline updates on cancer drugs. Get all the cancer drugs breaking news updates, videos, photostories and more at Business Standard.

Bank of America Global Healthcare Conference 2026 May 12, 2026 2:20 PM EDTCompany ParticipantsLavina Talukdar - Senior VP & Head ...